trending Market Intelligence /marketintelligence/en/news-insights/trending/D6mMIrQ-8brQ3esnBtGlCQ2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In this list

Anchiano Therapeutics to delist ordinary shares from Tel Aviv Stock Exchange

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Anchiano Therapeutics to delist ordinary shares from Tel Aviv Stock Exchange

Anchiano Therapeutics Ltd will voluntarily delist its ordinary shares from the Tel Aviv Stock Exchange on June 17.

The American depositary shares of Israel-based biotechnology company will continue trading on the Nasdaq Capital Market under the symbol ANCN.

Shareholders can convert their ordinary shares listed on the Tel Aviv Stock Exchange to ADSs. The company will issue one ADS in exchange for every 5 ordinary shares.

According to a March 14 press release, the company's board and management believe the decision to delist from the Tel Aviv Stock Exchange will maximize shareholder value.

The company completed an IPO of 2,652,174 ADSs with gross proceeds of $30.5 million and started trading on the Nasdaq Capital Market in February.

Anchiano is developing a potential bladder cancer treatment called inodiftagene vixteplasmid, which works by delivering a toxic gene to bladder cells that selectively kills tumor cells.